Search Results - "Sciot, R"

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M.G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L.H., Hennig, I., Strauss, S., Zakotnik, B., Anthoney, A., Albiges, L., Blay, J.-Y., Reichardt, P., Sufliarsky, J., van der Graaf, W.T.A., Debiec-Rychter, M., Sciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S., Stacchiotti, S.

“…Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

“…Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and…”
Get full text

Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease by Van Assche, Gert, Van Ranst, Marc, Sciot, Raf, Dubois, Bénédicte, Vermeire, Séverine, Noman, Maja, Verbeeck, Jannick, Geboes, Karel, Robberecht, Wim, Rutgeerts, Paul

“…In a man with Crohn's disease who was treated with natalizumab and subsequently died, reexamination showed that the fatal lesion was progressive multifocal…”
Get full text

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification by Cornillie, J., Wozniak, A., Li, H., Gebreyohannes, Y. K., Wellens, J., Hompes, D., Debiec-Rychter, M., Sciot, R., Schöffski, P.

“…Purpose Dedifferentiated liposarcoma (DDLPS) is a soft tissue malignancy characterized by amplification of the mouse double minute 2 homolog ( MDM2 ) gene…”
Get full text

Cellular and molecular features related to exceptional therapy response and extreme long‐term survival in glioblastoma by Decraene, B., Vanmechelen, M., Clement, P., Daisne, J. F., Vanden Bempt, I., Sciot, R., Garg, A. D., Agostinis, P., De Smet, F., De Vleeschouwer, S.

“…Glioblastoma Multiforme (GBM) remains the most common malignant primary brain tumor with a dismal prognosis that rarely exceeds beyond 2 years despite…”
Get full text

Is Neuroradiology Complementary to Histopathology in Central Nervous System Tumors with an Alteration of the BCOR Gene? by Nikoghosyan, A., Sciot, R., Jacobs, S. A., Verhaaren, B. F. J.

Get full text

MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas by Missiaglia, E, Shepherd, C J, Patel, S, Thway, K, Pierron, G, Pritchard-Jones, K, Renard, M, Sciot, R, Rao, P, Oberlin, O, Delattre, O, Shipley, J

“…Background: Rhabdomyosarcomas (RMSs) are primarily paediatric sarcomas that resemble developing skeletal muscle. Our aim was to determine the effects of…”
Get full text

Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis by Hauben, E., Sciot, Raf, Bechter, Oliver E., Beuselinck, B., Woei-A-Jin, F. J. S. H., Dumez, Herlinde, Nafteux, P., Wessels, T., Van Raemdonck, D., Coosemans, W., De Leyn, P., Sinnaeve, Friedl, Stas, M., Hompes, Daphne, Timmermans, I., Schöffski, Patrick, Clement, Paul M.

“…Background. Solitary fibrous tumor (SFT) is a rare variant of soft tissue sarcoma (STS). Materials and Methods. We reviewed SFT patients (pts) treated at our…”
Get full text

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours by Gits, C M M, van Kuijk, P F, Jonkers, M B E, Boersma, A W M, van IJcken, W F, Wozniak, A, Sciot, R, Rutkowski, P, Schöffski, P, Taguchi, T, Mathijssen, R H J, Verweij, J, Sleijfer, S, Debiec-Rychter, M, Wiemer, E A C

“…Background: Gastrointestinal stromal tumours (GIST) are characterised by high expression of KIT and ETV1, which cooperate in GIST oncogenesis. Our aim was to…”
Get full text

Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO by Blay, J.-Y., Bonvalot, S., Casali, P., Choi, H., Debiec-Richter, M., Dei Tos, A. P., Emile, J.-F., Gronchi, A., Hogendoorn, P. C. W., Joensuu, H., Le Cesne, A., Mac Clure, J., Maurel, J., Nupponen, N., Ray-Coquard, I., Reichardt, P., Sciot, R., Stroobants, S., van Glabbeke, M., van Oosterom, A., Demetri, G. D.

“…Background: The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives of this international…”
Get full text

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group by Debiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., Scurr, M., Hagemeijer, A., Van Glabbeke, M., van Oosterom, A.T.

“…Previous studies have shown that activating mutations of c-KIT/ PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the…”
Get full text

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management by Dômont, J, Salas, S, Lacroix, L, Brouste, V, Saulnier, P, Terrier, P, Ranchère, D, Neuville, A, Leroux, A, Guillou, L, Sciot, R, Collin, F, Dufresne, A, Blay, J-Y, Le Cesne, A, Coindre, J-M, Bonvalot, S, Bénard, J

“…Background: Fibromatosis comprises distinct clinical entities, including sporadic extra-abdominal fibromatosis, which have a high tendency for recurrence, even…”
Get full text

1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma by Mackintosh, C, Ordóñez, J L, García-Domínguez, D J, Sevillano, V, Llombart-Bosch, A, Szuhai, K, Scotlandi, K, Alberghini, M, Sciot, R, Sinnaeve, F, Hogendoorn, P C W, Picci, P, Knuutila, S, Dirksen, U, Debiec-Rychter, M, Schaefer, K-L, de Álava, E

“…Despite extensive characterization of the role of the EWS-ETS fusions, little is known about secondary genetic alterations and their clinical contribution to…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

Get full text

Cellular angiofibroma: another mesenchymal tumour with 13q14 involvement, suggesting a link with spindle cell lipoma and (extra)mammary myofibroblastoma by Maggiani, F, Debiec-Rychter, M, Vanbockrijck, M, Sciot, R

Get full text

Defining pseudoprogression in glioblastoma multiforme by Van Mieghem, E., Wozniak, A., Geussens, Y., Menten, J., De Vleeschouwer, S., Van Calenbergh, F., Sciot, R., Van Gool, S., Bechter, O. E., Demaerel, P., Wilms, G., Clement, P. M.

“…Background and purpose Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide…”
Get full text

Corrigendum to “Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis” by Schöffski, P., Timmermans, I., Hompes, D., Stas, M., Boecxstaens, Veerle, Sinnaeve, F., De Leyn, P., Coosemans, W., Van Raemdonck, D., Hauben, E., Sciot, R., Clement, P., Bechter, O., Beuselinck, B., Woei-A-Jin, F. J. S. H., Dumez, H., Nafteux, P., Wessels, T.

“…[This corrects the article DOI: 10.1155/2020/1385978.]…”
Get full text

Elevated Risk for MPNST in NF1 Microdeletion Patients by De Raedt, T., Brems, H., Wolkenstein, P., Vidaud, D., Pilotti, S., Perrone, F., Mautner, V., Frahm, S., Sciot, R., Legius, E.

“…An NF1 microdeletion is the single most commonly reported mutation in individuals with neurofibromatosis type 1 (NF1). Individuals with an NF1 microdeletion…”
Get full text

A phase II trial with rosiglitazone in liposarcoma patients by DEBROCK, G, VANHENTENRIJK, V, SCIOT, R, DEBIEC-RYCHTER, M, OYEN, R, VAN OOSTEROM, A

“…Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte…”
Get full text

Spinal Dermal Sinuses and Dermal Sinus-Like Stalks: Retrospective Analysis of 14 Cases and Possible Embryological Mechanisms by De Vloo, P, Sciot, R, Van Calenbergh, F

Get full text